Lyka Labs Limited, a pharmaceutical company listed on both BSE and NSE, has announced a major corporate development regarding its merger with Lyka Exports Limited. The company informed the stock exchanges that the Scheme of Amalgamation has now become effective following regulatory approvals.

This update has been disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency for investors and stakeholders.

NCLT Approval and Effective Date of Merger

The merger scheme was approved by the Hon’ble National Company Law Tribunal (NCLT), Ahmedabad Bench, through an order dated March 16, 2026.

Key Timeline:

• NCLT Approval Date: March 16, 2026
• Certified Copy Received: March 24, 2026
• Filing with ROC: April 8, 2026
• Effective Date of Scheme: April 8, 2026
• Appointed Date: April 1, 2022

The filing of the NCLT order with the Registrar of Companies (ROC) marks the final step, making the merger legally effective.

Details of the Amalgamation

Under the scheme:

• Lyka Exports Limited is the Transferor Company
• Lyka Labs Limited is the Transferee Company

The merger involves consolidation of both entities along with their shareholders and creditors, resulting in a unified corporate structure.

Impact on Share Capital Structure

One of the key outcomes of the merger is the increase in authorized share capital of Lyka Labs.

Revised Authorized Share Capital:

• Total: Rs. 59 crore
• Equity Shares: 5,70,00,000 shares of Rs. 10 each
• Preference Shares: 2,00,000 shares of Rs. 100 each

This increase reflects the combined capital structure of both companies after the amalgamation.

The change has also led to an update in Clause V of the Memorandum of Association (MoA) of the company.

Strategic Importance of the Merger

The amalgamation is a strategic move aimed at strengthening the company’s overall operations.

Key Benefits:

1. Business Consolidation

The merger brings both entities under a single structure, enabling:

• Simplified operations
• Better resource utilisation
• Streamlined decision-making

2. Improved Operational Efficiency

Combining operations can lead to:

• Reduction in administrative costs
• Enhanced process efficiency
• Better supply chain management

3. Enhanced Growth Opportunities

The unified entity can:

• Focus on expansion strategies
• Strengthen its market position
• Explore new business opportunities

Significance for Shareholders and Investors

For shareholders, the merger can have several implications:

Positive Aspects:

• Stronger financial and operational base
• Potential for improved profitability
• Better long-term value creation

Points to Consider:

• Integration challenges
• Changes in financial reporting
• Market reaction in the short term

Overall, such mergers are generally viewed as positive when they lead to operational synergies.

Pharmaceutical Sector Outlook

The pharmaceutical sector in India is one of the fastest-growing industries, driven by:

• Increasing healthcare demand
• Growth in exports
• Government support for domestic manufacturing
• Rising focus on research and development

Companies like Lyka Labs are expected to benefit from these trends, especially after consolidation.

Regulatory Compliance and Transparency

The company has ensured compliance with:

• SEBI (LODR) Regulations, 2015
• NCLT requirements
• ROC filing procedures

This demonstrates Lyka Labs’ commitment to:

• Transparency
• Corporate governance
• Investor communication

Market Perspective

From a market standpoint, the merger is a strategic positive development.

Key Positives:

• Consolidation of operations
• Increased capital base
• Improved efficiency

Potential Risks:

• Integration challenges
• Execution risks

Investors should monitor how effectively the company integrates the operations and realises synergies.

Future Outlook for Lyka Labs

With the merger now effective, Lyka Labs is expected to focus on:

• Business expansion
• Improving operational efficiency
• Strengthening its product portfolio

The company’s ability to leverage synergies from the merger will be crucial for its future performance.